— Know what they know.
Not Investment Advice

EVOK NASDAQ

Evoke Pharma, Inc.
1W: +0.6% 1M: +2.9% 3M: +116.1% 1Y: +154.6% 3Y: -46.1% 5Y: -97.4%
$11.00
Last traded 2025-12-16 — delisted
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · $18.9M mcap · 1M float · 7.17% daily turnover · Short 35% of daily vol

Balance Sheet Trends

Total Assets
$18M +147.8% ▲
5Y CAGR: +22.3%
Total Liabilities
$10M +8.6% ▲
5Y CAGR: +39.1%
Shareholders Equity
$7M +372.8% ▲
5Y CAGR: +9.9%
Cash & Investments
$14M +186.9% ▲
5Y CAGR: +19.1%
Total Debt
$5M +3.2% ▲
5Y CAGR: +106.2%
Net Debt
-$8M -3337.5% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2020FY2021FY2022FY2023FY2024
— Assets —
Cash$8M$9M$10M$5M$14M
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$8M$9M$10M$5M$14M
Net Receivables$23K$295K$625K$673K$2M
Inventory$236K$186K$289K$482K$445K
Other Current Assets$30K$12K$12K$48K$44K
Total Current Assets$9M$11M$12M$7M$17M
Property, Plant & Equip.$142K$12K$129K$0$154K
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$12K$0$0$242K$127K
Total Non-Current Assets$153K$12K$129K$242K$281K
Total Assets$9M$11M$12M$7M$18M
— Liabilities —
Accounts Payable$1M$874K$868K$2M$2M
Short-Term Debt$104K$0$0$5M$5M
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$5M$519K$66K$1M$100K
Total Current Liabilities$8M$1M$2M$10M$10M
Long-Term Debt$5M$5M$5M$5M$0
Other Non-Current Liab.$113K$612K$1M-$5M$0
Total Non-Current Liabilities$5M$6M$6M$0$101K
Total Liabilities$13M$7M$8M$10M$10M
— Equity —
Common Stock$3K$272$334$28$149
Retained Earnings-$99M-$107M-$116M-$123M-$129M
Accumulated OCI-$0$0$0$0-$0
Total Stockholders Equity-$3M$4M$4M-$3M$7M
Total Liabilities & Equity$9M$11M$12M$7M$18M
— Key Metrics —
Total Debt$5M$5M$5M$10M$5M
Net Debt-$3M-$4M-$5M$5M-$8M
Total Investments$0$0$0$0$0

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms